Efficacy of Optimized Treatment Protocol Using LAU-7b Formulation against Ovalbumin (OVA) and House Dust Mite (HDM) -Induced Allergic Asthma in Atopic Hyperresponsive A/J Mice
Language English Country United States Media electronic
Document type Journal Article
PubMed
31915990
DOI
10.1007/s11095-019-2743-z
PII: 10.1007/s11095-019-2743-z
Knihovny.cz E-resources
- Keywords
- LAU-7b, allergic asthma, fenretinide, very long chain ceramides,
- MeSH
- Allergens immunology MeSH
- Asthma drug therapy immunology metabolism MeSH
- Ceramides metabolism MeSH
- Fenretinide therapeutic use MeSH
- Clinical Protocols MeSH
- Methylcellulose chemistry MeSH
- Disease Models, Animal MeSH
- Mice MeSH
- Ovalbumin immunology MeSH
- Drug Compounding MeSH
- Pyroglyphidae immunology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Allergens MeSH
- Ceramides MeSH
- Fenretinide MeSH
- Methylcellulose MeSH
- Ovalbumin MeSH
PURPOSE: To assess the efficacy of the novel clinical formulation of fenretinide (LAU-7b) for the treatment of allergic asthma. To study the association between LAU-7b treatment in allergic asthma and the modulation of very long chain ceramides (VLCC). METHODS: We used two allergens (OVA and HDM) to induce asthma in mouse models and we established a treatment protocol with LAU-7b. The severity of allergic asthma reaction was quantified by measuring the airway resistance, quantifying lung inflammatory cell infiltration (Haematoxylin and eosin stain) and mucus production (Periodic acid Schiff satin). IgE levels were measured by ELISA. Immunophenotyping of T cells was done using Fluorescence-activated cell sorting (FACS) analysis. The analysis of the specific species of lipids and markers of oxidation was performed using mass spectrometry. RESULTS: Our data demonstrate that 10 mg/kg of LAU-7b was able to protect OVA- and HDM-challenged mice against increase in airway hyperresponsiveness, influx of inflammatory cells into the airways, and mucus production without affecting IgE levels. Treatment with LAU-7b significantly increased percentage of regulatory T cells and CD4+ IL-10-producing T cells and significantly decreased percentage of CD4+ IL-4-producing T cells. Our data also demonstrate a strong association between the improvement in the lung physiology and histology parameters and the drug-induced normalization of the aberrant distribution of ceramides in allergic mice. CONCLUSION: 9 days of 10 mg/kg of LAU-7b daily treatment protects the mice against allergen-induced asthma and restores VLCC levels in the lungs and plasma.
Department of Human Genetics McGill University Montreal Quebec Canada
Department of Medicine Division of Experimental Medicine McGill University Montreal Quebec Canada
See more in PubMed
J Mol Med (Berl). 2017 Oct;95(10):1053-1064 PubMed
Retina. 2013 Mar;33(3):498-507 PubMed
J Clin Oncol. 2001 Mar 15;19(6):1664-70 PubMed
Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G528-37 PubMed
Nat Med. 2012 May 04;18(5):716-25 PubMed
J Endocrinol. 2003 Sep;178(3):347-55 PubMed
J Endocrinol. 2003 Jul;178(1):1-4 PubMed
Int J Mol Sci. 2019 Mar 20;20(6): PubMed
Prog Lipid Res. 2012 Jan;51(1):50-62 PubMed
Clin Cancer Res. 2007 May 15;13(10):3079-86 PubMed
J Cyst Fibros. 2019 Nov;18(6):781-789 PubMed
Prog Lipid Res. 2019 Apr;74:130-144 PubMed
Am J Respir Cell Mol Biol. 2014 Dec;51(6):783-92 PubMed
Eur J Pharmacol. 2015 Jul 15;759:272-7 PubMed
J Cyst Fibros. 2019 May;18(3):349-356 PubMed
Am J Respir Crit Care Med. 2019 Feb 15;199(4):478-488 PubMed
Exp Biol Med (Maywood). 2017 Jun;242(11):1178-1184 PubMed
Respir Med. 2006 Aug;100(8):1307-17 PubMed
Pharmacol Ther. 2002 Oct;96(1):23-43 PubMed
Can Respir J. 2012 Mar-Apr;19(2):127-64 PubMed
Clin Cancer Res. 2008 Jan 1;14(1):224-9 PubMed
Am J Respir Cell Mol Biol. 2009 Jul;41(1):100-6 PubMed
J Biol Chem. 1957 May;226(1):497-509 PubMed
Clin Cancer Res. 2017 Aug 15;23(16):4550-4555 PubMed
Annu Rev Pharmacol Toxicol. 2015;55:129-47 PubMed
Int J Pharm. 2018 Mar 1;538(1-2):48-56 PubMed
J Asthma Allergy. 2017 Nov 07;10:293-301 PubMed
Int Arch Allergy Immunol. 2015;166(4):243-58 PubMed
Am J Respir Crit Care Med. 2004 Feb 1;169(3):378-85 PubMed
Mamm Genome. 2018 Apr;29(3-4):281-298 PubMed
Biochim Biophys Acta. 2015 Oct;1848(10 Pt A):2374-84 PubMed
J Neurosci. 2010 Mar 3;30(9):3220-6 PubMed
Adv Drug Deliv Rev. 2018 Aug;133:19-33 PubMed
Cancer Chemother Pharmacol. 2010 Oct;66(5):845-50 PubMed
Eur Respir J. 2015 Feb;45(2):396-407 PubMed
Int Immunopharmacol. 2006 Nov;6(11):1651-64 PubMed
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1914-9 PubMed
Am J Respir Cell Mol Biol. 2008 Jan;38(1):47-56 PubMed
Biochim Biophys Acta. 2015 Feb;1848(2):561-7 PubMed
J Biol Chem. 2012 Jun 15;287(25):21025-33 PubMed
Nature. 1999 Nov 25;402(6760 Suppl):B18-23 PubMed
